All In MedTech

Device Trial Radar · NCT02700984

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

An Observational Multicenter Clinical Study to Assess the Long-Term Safety of the CyPass Micro-Stent in Patients With Primary Open Angle Glaucoma Who Have Completed Participation in the COMPASS Trial

Last checked: Nov 20, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

282

Actual

Start

Mar 30, 2016

Primary completion

Apr 18, 2018

Study completion Apr 18, 2018

Sponsor

Lead sponsor
Alcon ResearchNot on our public-company list
Sponsor type
Industry
Collaborators
Transcend Medical, Inc.
First posted
Mar 7, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety of the CyPass Micro-Stent in subjects who completed Study Protocol TMI-09-01, COMPASS Trial.

Conditions

  • Primary Open Angle Glaucoma (POAG)

Interventions

  • CyPass Micro-StentDevice

    The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.

  • Cataract SurgeryProcedure

    Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-year Annualized Rate (Percentage) of Sight-threatening Adverse Events, by Treatment GroupTime frame: Up to Month 60 postoperative

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Alcon Investigative Site

    Glendale, Arizona

  • Alcon Investigative Site

    Fayetteville, Arkansas

  • Alcon Investigative Site

    La Jolla, California

19 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.